Citius Pharmaceuticals (NASDAQ:CTXR) vs. Exicure (NASDAQ:XCUR) Critical Analysis

Citius Pharmaceuticals (NASDAQ:CTXRGet Rating) and Exicure (NASDAQ:XCURGet Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation.

Volatility and Risk

Citius Pharmaceuticals has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500. Comparatively, Exicure has a beta of 1.45, indicating that its share price is 45% more volatile than the S&P 500.

Valuation & Earnings

This table compares Citius Pharmaceuticals and Exicure’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Citius Pharmaceuticals N/A N/A -$23.05 million ($0.20) -5.85
Exicure $16.61 million 0.47 -$64.10 million ($16.37) -0.10

Citius Pharmaceuticals has higher earnings, but lower revenue than Exicure. Citius Pharmaceuticals is trading at a lower price-to-earnings ratio than Exicure, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Citius Pharmaceuticals and Exicure’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Citius Pharmaceuticals N/A -24.78% -22.97%
Exicure N/A -718.23% -95.97%

Insider and Institutional Ownership

25.4% of Citius Pharmaceuticals shares are owned by institutional investors. 14.8% of Citius Pharmaceuticals shares are owned by insiders. Comparatively, 8.4% of Exicure shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Citius Pharmaceuticals and Exicure, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Citius Pharmaceuticals 0 0 2 0 3.00
Exicure 0 1 0 0 2.00

Citius Pharmaceuticals presently has a consensus target price of $5.00, indicating a potential upside of 327.35%. Exicure has a consensus target price of $67.50, indicating a potential upside of 4,226.92%. Given Exicure’s higher possible upside, analysts clearly believe Exicure is more favorable than Citius Pharmaceuticals.

Summary

Citius Pharmaceuticals beats Exicure on 8 of the 12 factors compared between the two stocks.

About Citius Pharmaceuticals

(Get Rating)

Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

About Exicure

(Get Rating)

Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.

Receive News & Ratings for Citius Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Citius Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.